Clinical Trials Logo

Lung Adenocarcinoma clinical trials

View clinical trials related to Lung Adenocarcinoma.

Filter by:

NCT ID: NCT01249066 Recruiting - Lung Adenocarcinoma Clinical Trials

Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma

Start date: September 2010
Phase: N/A
Study type: Observational

AMP-activated protein kinase (AMPK) is an evolutionally conserved protein kinase that serves as an energy guardian to help cells adapt to various metabolic stress including hypoxia. Because the role of AMPK in cancers has not been fully elucidated, in this study we investigated the expression and activation of AMPK in lung adenocarcinoma (LADC) cells and tissue.

NCT ID: NCT01249053 Recruiting - Lung Adenocarcinoma Clinical Trials

Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma

Start date: August 2010
Phase: N/A
Study type: Observational

Optic atrophy type 1(OPA1) is a nuclear dynamin-related GTPase, targeted to the inner mitochondrial membrane, which plays a role in mitochondrial fusion. Mitochondria fusion is associated with process of apoptosis. . OPA1 plays an important role in the mitochondrial bioenergetics and mitochondrial networks. The changes in mitochondrial shape and mitochondrial bioenergetics may be cause of the disease. In this study, we investigate the expression of OPA1 in lung adenocarcinoma (LADC) cells and tissue.